rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    ACRV
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Acrivon Reports Third Quarter 2026 Financial Results and Business Highlights
      Nov 16Yahoo FinanceACRV
      Acrivon Therapeutics, Inc. (ACRV) Discusses ACR-525 Acquisition and PKC Inhibitor Preclinical Program - Slideshow
      Nov 13Seeking AlphaACRV
      Jefferies reiterates Acrivon Therapeutics stock rating on drug development path
      Nov 11Investing.comACRV
      Acrivon acquires JAK1 inhibitor to expand into immunology
      Nov 6Investing.comACRV
      Acrivon Expands into Immunology and Inflammation with Acquisition of Phase 2-Ready Differentiated, Oral JAK1 Inhibitor ACR-525, and PKCθ Inhibitor Preclinical Program from Aqilion AB

      Asset acquisition establishes immunology and inflammation (I&I) as a strategic pillar alongside oncology, extending the company into autoimmune disease As part of Acrivon’s due diligence, extensive AP3 profiling against approved JAK inhibitors and dupilumab revealed ACR-525 as a highly-selective, potentially best-in-class JAK1 inhibitor Eosinophilic esophagitis (EoE) targeted as first potential indication using a Phase 2-ready formulation of ACR-525 designed for patients with difficulty swallowi

      Nov 6Yahoo FinanceACRV
      Acrivon to Present Late-Breaking Oral Plenary Presentation and Posters at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
      Nov 4Yahoo FinanceACRV
      Acrivon to present cancer drug trial data at November symposium
      Oct 29Investing.comACRV
      Acrivon Announces Late-Breaking Oral Plenary Presentation of Early Phase 1/2 Clinical Results in AP3-Predicted Tumors for its First-in-Class WEE1/PKMYT1 Inhibitor ACR-2316 at the 38th EORTC-NCI-AACR Symposium
      Oct 29Yahoo FinanceACRV
      Acrivon advances CDK11 inhibitor for AML, targets 2027 IND filing
      Oct 20Investing.comACRV
      Acrivon Advances ACR-7280, an Optimized, AP3-Enabled, Potential First-in-Class, Oral CDK11 Inhibitor Toward IND Filing in First Half of 2027
      Oct 20Yahoo FinanceACRV
      Acrivon Therapeutics chief legal officer sells $585 in stock
      Oct 7Investing.comACRV
      What Makes Acrivon Therapeutics, Inc. (ACRV) a New Buy Stock

      Acrivon Therapeutics, Inc. (ACRV) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

      Sep 15Yahoo FinanceACRV
      Acrivon Therapeutics at 12th annual Cantor Fitzgerald conference: platform push
      Sep 9Investing.comACRV
      Acrivon Therapeutics, Inc. (ACRV) Just Flashed Golden Cross Signal: Do You Buy?
      Sep 3Yahoo FinanceACRV
      Acrivon Therapeutics to Present at the 2026 Cantor Global Healthcare Conference

      WATERTOWN, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biotechnology company discovering and developing precision medicines utilizing its proprietary Generative Phosphoproteomics AP3 (Acrivon Predictive Precision Proteomics) platform deployed for rational drug design and predictive clinical development, today announced the company’s president and chief executive officer, Peter Blume-Jensen, M.D., Ph.D

      Sep 2Yahoo FinanceACRV
      acrivon appoints michaela levin as chief business officer
      Aug 31Investing.comACRV
      Acrivon Therapeutics Appoints Michaela Levin, Ph.D., as Chief Business Officer
      Aug 31Yahoo FinanceACRV
      Here's Why Acrivon Therapeutics, Inc. (ACRV) is a Great Momentum Stock to Buy

      Does Acrivon Therapeutics, Inc. (ACRV) have what it takes to be a top stock pick for momentum investors? Let's find out.

      Aug 24Yahoo FinanceACRV

      This is the newest page. Registered accounts read further back.